Rani Therapeutics
RANI
Rani Therapeutics (RANI) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- −$0.07
- EPS estimate
- −$0.05
- EPS surprise
- −47.37%
- Revenue surprise
- −70.78%
- Revenue
- $1.5M
- Revenue estimate
- $5.0M
- Reported
- Mar 26, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Mar 26, 2026 | −$0.05 | −$0.07 | −47.37% | $1.5M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.29 | −$0.18 | +36.84% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.28 | −$0.22 | +21.43% | $172,000.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.27 | −$0.27 | −0.45% | $1.0M | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.29 | −$0.24 | +17.24% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.34 | −$0.26 | +22.43% | $0.00 | SEC |
| Q1 2024 | May 6, 2024 | −$0.28 | −$0.29 | −4.32% | $0.00 | SEC |
| Q4 2023 | Mar 20, 2024 | −$0.38 | −$0.27 | +28.95% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.43 | −$0.36 | +15.49% | $0.00 | SEC |
| Q2 2023 | Aug 11, 2023 | −$0.42 | −$0.37 | +12.82% | $0.00 | SEC |
| Q1 2023 | May 10, 2023 | −$0.47 | −$0.33 | +29.34% | $0.00 | SEC |
| Q4 2022 | Mar 22, 2023 | −$0.40 | −$0.35 | +12.72% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.52 | −$0.33 | +37.13% | $0.00 | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.52 | −$0.31 | +39.92% | $0.00 | SEC |
| Q1 2022 | May 11, 2022 | −$0.66 | −$0.29 | +56.06% | $0.00 | SEC |
| Q4 2021 | Mar 29, 2022 | −$0.50 | −$0.27 | +45.45% | $0.00 | SEC |
| Q3 2021 | Nov 16, 2021 | −$0.18 | −$0.16 | +11.11% | $0.00 | SEC |
| Q2 2021 | Sep 13, 2021 | −$0.18 | −$0.12 | +31.82% | $2.0M | SEC |
Quarterly revenue
Frequently asked questions
When did Rani Therapeutics (RANI) last report earnings?
Rani Therapeutics last reported on Mar 26, 2026, covering fiscal Q4 2025.
Did RANI beat earnings estimates?
No. Rani Therapeutics reported EPS of −$0.07 for Q4 2025 against a −$0.05 estimate — a 47.37% miss.
How much revenue did RANI report last quarter?
Rani Therapeutics reported $1.5M in revenue for Q4 2025, against a consensus estimate of $5.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.